Argenica Therapeutics Ltd (AU:AGN)
ASX:AGN
AGN Stock Chart & Stats
AU$0.14
<AU$0.01(0.81%)
At close: 4:00 PM EST
AU$0.14
<AU$0.01(0.81%)
Day’s Range― - ―
52-Week RangeAU$0.13 - AU$0.85
Previous CloseN/A
Volume9.34K
Average Volume (3M)511.75K
Market Cap
AU$18.63M
Enterprise ValueAU$14.23M
Total Cash (Recent Filing)AU$10.56M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Mar 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding128,456,710
10 Day Avg. Volume288,263
30 Day Avg. Volume511,745
Financial Highlights & Ratios
PEG Ratio-2.24
Price to Book (P/B)13.39
Price to Sales (P/S)30.16
P/FCF Ratio-16.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.64Price Target Upside357.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.1
Revenue Forecast (FY)AU$27.40M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetNo reported debt lowers fixed obligations and preserves flexibility to fund R&D or restructure financing without near-term solvency pressure. Over a multi-month horizon this reduces default risk, improves bargaining power with partners/investors, and supports runway extension options.
Revenue Growth TrendSustained top-line growth demonstrates improving commercial or grant/licensing traction, increasing optionality to fund development and validate business progress. Over 2-6 months this trend supports credibility with partners and can reduce reliance on dilution if continued.
Focused Therapeutic Franchise Addressing Unmet NeedA clear, specialized focus on stroke neuroprotection targets a large, structurally growing unmet medical need. This concentration can create development expertise, clearer regulatory pathways and attractive licensing/partnering prospects if clinical data progress, a durable strategic advantage.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow forces continual external financing to sustain operations and trials. Over 2-6 months this raises dilution risk, constrains investment pacing, and can limit ability to pursue parallel trials or commercial activities without new capital.
Widening Losses And Declining EquityMaterial equity erosion and widening losses reduce the balance sheet cushion and increase sensitivity to funding gaps. Over the medium term this amplifies financing risk, can raise cost of capital, and weakens investor flexibility to support high-cost clinical programs.
Development-stage Funding DependenceBeing development-stage with no current profitability means critical reliance on external grants, equity raises or partners. This structural dependence increases execution risk: trial timelines and binary outcomes can force reactive financing and dilute shareholders over multiple funding rounds.
Argenica Therapeutics Ltd News
AGN FAQ
What was Argenica Therapeutics Ltd’s price range in the past 12 months?
Argenica Therapeutics Ltd lowest share price was AU$0.13 and its highest was AU$0.85 in the past 12 months.
What is Argenica Therapeutics Ltd’s market cap?
Argenica Therapeutics Ltd’s market cap is AU$18.63M.
When is Argenica Therapeutics Ltd’s upcoming earnings report date?
Argenica Therapeutics Ltd’s upcoming earnings report date is Mar 02, 2027 which is in 327 days.
How were Argenica Therapeutics Ltd’s earnings last quarter?
Argenica Therapeutics Ltd released its earnings results on Feb 10, 2026. The company reported -AU$0.03 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.03.
Is Argenica Therapeutics Ltd overvalued?
According to Wall Street analysts Argenica Therapeutics Ltd’s price is currently Undervalued.
Does Argenica Therapeutics Ltd pay dividends?
Argenica Therapeutics Ltd does not currently pay dividends.
What is Argenica Therapeutics Ltd’s EPS estimate?
Argenica Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Argenica Therapeutics Ltd have?
Argenica Therapeutics Ltd has 128,456,710 shares outstanding.
What happened to Argenica Therapeutics Ltd’s price movement after its last earnings report?
Argenica Therapeutics Ltd reported an EPS of -AU$0.03 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.754%.
Which hedge fund is a major shareholder of Argenica Therapeutics Ltd?
Currently, no hedge funds are holding shares in AU:AGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Argenica Therapeutics Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.64 (357.14% Upside)
AU$0.64 (357.14% Upside)
Blogger Sentiment
Bullish
AU:AGN Sentiment 93%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.48%
12-Months-Change
Fundamentals
Return on Equity
-183.51%
Trailing 12-Months
Asset Growth
-66.25%
Trailing 12-Months
Company Description
Argenica Therapeutics Ltd
Argenica Therapeutics Limited engages in the research and development of a neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate use to protect brain cells and reduce cell death during a stroke and other types of neural injuries. The company was incorporated in 2019 and is based in Nedlands, Australia.
AGN Stock 12 Month Forecast
Average Price Target
AU$0.64
▲(357.14% Upside)
Technical Analysis
Alterity Therapeutics
―
Race Oncology Ltd.
―
Nanollose Ltd.
―
Avecho Biotechnology Limited
―
AdAlta Ltd.
―
Options Prices
Currently, No data available
---